Trenonacog alfa

Drug Profile

Trenonacog alfa

Alternative Names: Coagulation Factor IX (Recombinant) - Aptevo Therapeutics; IB-1001; IXINITY; Nonacog-alfa biosimilar - Emergent BioSolutions; Nonacog-alfa biosimilar - Inspiration; Recombinant factor IX biosimilar - Emergent BioSolutions; Recombinant factor IX biosimilar - Inspiration

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inspiration Biopharmaceuticals
  • Developer Aptevo Therapeutics; Cangene Corporation
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 10 Apr 2017 Pooled efficacy and adverse events data from two clinical trials in Haemophilia B released by Aptevo therapeutics (IV)
  • 22 Aug 2016 CanGene withdraws a phase III trial for Haemophilia B (in adolescents, in adults) in the USA and the United Kingdom prior to enrolment (NCT02048111)
  • 01 Aug 2016 Emergent BioSolutions forms a spin-off Aptevo Therapeutics for its oncology and haematology products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top